7
BRAF Second-line
Recommendation 8.1
➤ For patients with a BRAF V600E mutation who have had previous
BRAF/MEK (dabrafenib/trametinib) targeted therapy, clinicians
should offer standard first-line therapy based on the ASCO/OH non-
driver mutation guideline (Moderate recommendation; IC-L).
Recommendation 8.2
➤ For patients with a BRAF V600E mutation, if BRAF-targeted
therapy was not given in the first-line setting, clinicians may
offer dabrafenib/trametinib (Moderate recommendation; IC-L) or
dabrafenib alone (Weak recommendation; IC-L) or vemurafenib (Weak
recommendation; IC-B-L).
Recommendation 8.3
➤ For patients with a BRAF V600E mutation who have had previous
chemotherapy, immunotherapy, and/or BRAF-targeted therapy in
the first- or subsequent-line setting, clinicians should offer standard
treatment based on the ASCO/OH non-driver mutation guideline
(Moderate recommendation; IC-L).
Recommendation 8.4
➤ For patients with BRAF mutations other than BRAF V600E mutations,
clinicians should offer standard therapy based on the ASCO/OH non-
driver mutation guideline (Moderate recommendation; IC-L).
MET First-line
Recommendation 9.1
➤ For patients with a MET exon 14 skipping mutation, a performance
status of 0–2, previously untreated NSCLC, clinicians may offer
MET-targeted therapy with capmatinib or tepotinib (Moderate
recommendation; IC-L).
Recommendation 9.2
➤ For patients with a MET exon 14 skipping mutation, a performance
status of 0–2, previously untreated NSCLC, clinicians may offer
standard first-line therapy based on the ASCO/OH non-driver
mutations guideline (Moderate recommendation; IC-L).